Retatrutide’s influence on skin health operates through multiple pathways, including its anti-inflammatory mechanisms, metabolic improvements, and direct receptor interactions in skin tissue.
GLP-1 receptors aren’t just found in the pancreas and brain—they’re also expressed in skin cells, including keratinocytes and fibroblasts. When Retatrutide activates these receptors, it can trigger inflammatory signaling pathways that manifest as skin sensitivity, particularly in individuals with heightened immune responses.20
GLP-1 receptors can be found in a variety of tissues such as the pancreas, gastric mucosa, kidney, lung, heart, skin, immune cells, and brain.1 This presence of GLP-1 receptors in skin tissue suggests that retatrutide may exert direct effects on cutaneous health.
Glucagon-like peptide 1 receptor agonists (GLP-1RA) are commonly used as treatment for type 2 diabetes mellitus and obesity. GLP-1RA have been found to be valuable therapeutic approaches not only for glucose control, but also for weight loss and cardiovascular risk reduction. It has also been established that GLP-1RA have immunological and anti-inflammatory effects. The aim of this article was to comprehensively review the literature and to collect, analyse and quantitatively resynthesize evidence on the possible effects of GLP-1RA on inflammatory skin diseases. Through body weight reduction and subsequent systemic inflammation reduction, but mainly through their direct interaction with signalling pathways of inflammation and immune cells, GLP-1RA can improve psoriasis and hidradenitis suppurativa (HS). Clinical data of the positive effects of GLP-1RA in patients with psoriasis and HS are presented.21
The benefit that therapy with GLP-1RA has over other obesity treatments is the effect on the immune cells. GLP-1RA can reduce the production of proinflammatory cytokines such as IL-17, by inhibiting stimulating pathways of TNF-a and NF-kB.21
A study by Nicolau et al. stressed a significant improvement in HS severity in 14 obese patients with HS receiving liraglutide. After the treatment with liraglutide, patients average Hurley scores and DLQI were reduced, and there was also a significant reduction in ultrasensitive C-reactive protein and other systemic inflammatory markers. The improvement of HS was a result of weight loss.21
Peptide medications can trigger mast cell degranulation, releasing histamine and other inflammatory mediators. This explains why symptoms like itching, flushing, and localized redness are common. The effect is typically dose-dependent and diminishes as the body develops tolerance.20
Local reactions at injection sites are often mechanical rather than immunological. Factors include needle gauge, injection technique, temperature of the solution, and individual variations in subcutaneous tissue sensitivity.20
Some researchers use other peptides alongside retatrutide to promote tissue repair and have anti-inflammatory effects to support overall healing and reduce inflammatory responses. Oral collagen supplements (5-15g daily) support skin structure and hydration. This may help maintain skin integrity during rapid weight loss phases associated with Retatrutide use.20
The significant weight loss achieved with retatrutide may also impact skin health through improved metabolic parameters. Reduced systemic inflammation and improved insulin sensitivity can contribute to better overall skin condition and potentially improved wound healing capabilities.
